News & Events

NASHUA, N.H. –  April 8, 2025  – iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today announced the appointment of Mark Koeniguer as Chief Commercial Officer (CCO), to…

NASHUA, N.H. – March 19, 2025 – iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the fourth quarter and full…

NASHUA, N.H., March 11, 2025 — iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the fourth quarter and year ended December 31, 2024, after market close, and host a conference call at 4:30 PM Eastern Time…

healthandpharma.net: Oncolife

Radiology Today, March 2025

Imaging Technology News

Her breast health journey deserves trust and confidence—empower it with iCAD’s AI-powered solutions, offering faster, more precise insights to help you deliver exceptional care today—and tomorrow. With iCAD, reduce diagnostic uncertainty and ensure she gets the right care at the right time, giving her confidence and peace of mind.

Her breast health journey deserves trust and confidence—empower it with iCAD’s AI-powered solutions, offering faster, more precise insights to help you deliver exceptional care today—and tomorrow. With iCAD, reduce diagnostic uncertainty and ensure she gets the right care at the right time, giving her confidence and peace of mind.

Her breast health journey deserves trust and confidence—empower it with iCAD’s AI-powered solutions, offering faster, more precise insights to help you deliver exceptional care today—and tomorrow. With iCAD, reduce diagnostic uncertainty and ensure she gets the right care at the right time, giving her confidence and peace of mind.

Dr. Vautrin, a user of iCAD’s ProFound AI solution for 2D and 3D mammography for nearly two years, shares her experience through a series of clinical cases where the AI-provided insights were crucial in detecting cancer in her patients.

Apport des solutions d’intelligence artificielle d’iCAD pour un meilleur dépistage du cancer du sein détection, densité et risque : revue des dernières études cliniques et revue de cas. Présenté par Pr Bruno Boyer, CIMI, Paris

Utilisatrice de la solution ProFound IA d’iCAD pour les mammographies 2D et 3D depuis près de deux ans, le Dr Vautrin partage son retour d’expérience au travers d’une dizaine de cas cliniques pour lesquels les informations fournies par l’IA se sont avérées déterminantes pour détecter des cancers chez ses patientes.